Laurion Capital Management LP Protagonist Therapeutics, Inc Transaction History

Laurion Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $4.37 Million - $16.8 Million	-337,109 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$25.57 - $44.88 $4.85 Million - $8.51 Million	189,704 Added 128.7%	337,109 $15.1 Million
Q1 2021 May 14, 2021	BUY	$19.02 - $31.15 $328,037 - $537,244	17,247 Added 13.25%	147,405 $3.82 Million
Q4 2020 Feb 12, 2021	BUY	$18.49 - $25.13 $2.41 Million - $3.27 Million	130,158 New	130,158 $2.62 Million
Q2 2019 Aug 13, 2019	SELL	$8.98 - $12.96 $769,056 - $1.11 Million	-85,641 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$6.5 - $13.77 $445,516 - $943,809	68,541 Added 400.82%	85,641 $1.08 Million
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $304,554 - $504,690	-48,342 Reduced 73.87%	17,100 $115,000
Q3 2018 Nov 13, 2018	BUY	$6.82 - $11.26 $446,314 - $736,876	65,442 New	65,442 $673,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.